BCTXZ
BriaCell Therapeutics Corp. Warrant
NASDAQ · Healthcare · Biotechnology · CA
$0.19
−2.37%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 26.6K | 107.9K | — | — | — |
| Gross Profit | (26.6K) | (107.9K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 25.8M | 21.5M | 27.2M | 15.3M | 8.0M |
| SG&A Expense | 6.2M | 5.9M | 6.2M | 7.9M | 7.3M |
| General & Admin Expense | 4.8M | — | 6.2M | 7.9M | 7.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 32.0M | 27.4M | 33.3M | 23.3M | 15.3M |
| Cost and Expenses | 32.0M | 27.5M | 33.3M | 23.3M | 15.3M |
| Operating Income (EBIT) | (32.0M) | (27.5M) | (33.3M) | (23.3M) | (15.3M) |
| Non-Operating | |||||
| Interest Income | 406.7K | 121.4K | 288.0K | 891.2K | 136.7K |
| Interest Expense | 29.6K | 37.4K | — | — | 979.00 |
| Net Interest Income | 377.1K | 84.0K | 288.0K | 891.2K | 135.8K |
| Other Non-Op Income/Expense | 1.1M | 656.6K | 28.4M | 3.0M | (11.5M) |
| Non-Operating Income (excl Interest) | (413.4K) | — | (28.4M) | — | 11.5M |
| EBT (Pre-Tax Income) | (31.0M) | (26.9M) | (4.9M) | (20.3M) | (26.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (30.7M) | (26.6M) | (4.8M) | (20.3M) | (26.8M) |
| Earnings from Cont. Ops | (31.0M) | (26.9M) | (4.9M) | (20.3M) | (26.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (30.7M) | (26.6M) | (4.8M) | (20.3M) | (26.8M) |
| Per Share | |||||
| Basic EPS | ($12.20) | ($62.95) | ($43.68) | ($195.00) | ($259.50) |
| Diluted EPS | ($12.20) | ($62.95) | ($43.68) | ($195.00) | ($259.50) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 7.3M | 423114 | 109699 | 104131 | 103293 |
| Diluted Shares Outstanding | 7.3M | 423114 | 109699 | 104131 | 103293 |
| Profitability Metrics | |||||
| EBITDA | (31.5M) | (27.4M) | (4.8M) | (23.3M) | (26.8M) |
| D&A | 112.9K | 107.9K | 83.9K | 15.3K | 15.3K |
| EBIT | (31.6M) | (27.5M) | (4.9M) | (23.3M) | (26.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Apr 1, 2026